AZD2461: Novel PARP Inhibitor for Robust DNA Repair Modulation

Executive Summary: AZD2461 is a poly (ADP-ribose) polymerase (PARP) inhibitor with a potent IC50 of 5 nM, demonstrating cytotoxicity in human breast cancer cell lines and proven efficacy in BRCA1-mutated mouse tumor models (APExBIO). The compound exhibits lower affinity for P-glycoprotein (Pgp) than olaparib, providing a mechanistic rationale for its use against drug-resistant cancers (AZD3514.com). AZD2461 induces G2 phase cell cycle arrest, reduces S phase cell populations, and sustains PARP inhibition for several hours in vivo. Typical experimental concentrations range from 5 to 50 μM with 48–72 hour incubation for in vitro studies (Schwartz 2022). Long-term administration extends relapse-free survival in preclinical models while maintaining tolerability.

Biological Rationale

PARP enzymes, particularly PARP-1, are essential for the repair of single-strand DNA breaks via the base excision repair pathway. Inhibition of PARP activity impairs DNA repair, leading to accumulation of DNA damage and cell death, especially in cells with deficient homologous recombination (e.g., BRCA1-mutated cancers) (Schwartz 2022). Targeting PARP is a validated strategy to exploit synthetic lethality in cancer therapy. High PARP activity is a hallmark of certain breast cancer subtypes (AZD3514.com). The ability of AZD2461 to evade Pgp-mediated efflux addresses a common resistance mechanism observed with earlier PARP inhibitors (AZD7687.com). This expands its utility in models where multidrug resistance proteins are overexpressed.

Mechanism of Action of AZD2461

AZD2461 is a selective PARP-1 inhibitor with an IC50 value of 5 nM, as characterized via biochemical enzymatic assays (APExBIO). By competitively binding to the NAD⁺ binding site of PARP-1, AZD2461 blocks the enzyme's catalytic activity, preventing poly-ADP-ribosylation of target proteins. This leads to impaired DNA repair, cell cycle arrest at the G2 phase, and subsequent apoptosis in susceptible cancer cells. In breast cancer cell lines MCF-7 and SKBR-3, AZD2461 reduces viable cell numbers in a concentration- and time-dependent manner (Schwartz 2022). In in vivo murine KB1P tumor models, PARP inhibition is observable for several hours post-treatment, with restoration of PAR levels by 24 hours. The compound's lower affinity for Pgp compared to olaparib results in increased intracellular retention and efficacy in Pgp-overexpressing models.

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 with an IC50 of 5 nM under standard in vitro assay conditions (pH 7.4, 25°C) (APExBIO).
• In MCF-7 and SKBR-3 breast cancer cell lines, AZD2461 decreases cell viability in a dose- and time-dependent manner at concentrations ranging from 5–50 μM after 48–72 hours of incubation (Schwartz 2022).
• AZD2461 induces G2 phase cell cycle arrest, with a corresponding reduction in S phase cells, as quantified by flow cytometry in treated cultures (Schwartz 2022).
• In mouse models bearing BRCA1-mutated KB1P tumors, a single AZD2461 dose sustains PARP inhibition for several hours, with PAR levels returning to baseline after 24 hours (Schwartz 2022).
• Long-term administration of AZD2461 (dosing regimen: 5–10 mg/kg, daily, up to 28 days) is well-tolerated and significantly prolongs median relapse-free survival in tumor-bearing mice (Schwartz 2022).
• AZD2461 demonstrates lower affinity for Pgp transporters compared to olaparib, enhancing its retention and activity in Pgp-overexpressing cells (AZD3514.com).

This article provides updated mechanistic context and structured performance benchmarks compared to AZD2461: Novel PARP Inhibitor Redefining DNA Repair Research, which primarily reviews pathway modulation. Our article specifies quantitative performance, solubility, and protocol parameters for translational workflows.

Applications, Limits & Misconceptions

AZD2461 is suitable for in vitro and in vivo research applications targeting DNA repair pathways, particularly in breast cancer and BRCA1/2-mutated tumor models. Its lower Pgp affinity supports use in multidrug-resistant cancer models. The compound is not intended for clinical or diagnostic use in humans and should be handled as a research reagent. AZD2461 is insoluble in water but dissolves readily in DMSO (≥16.35 mg/mL) and ethanol (≥45.2 mg/mL with ultrasonic assistance). Storage at -20°C is recommended for solid form; solutions should be prepared fresh for short-term experimental use.

Common Pitfalls or Misconceptions

• AZD2461 is not effective in cancers lacking PARP dependency or homologous recombination deficiency.
• It does not overcome all forms of drug resistance, specifically non-Pgp mediated mechanisms.
• The compound is not suitable for oral administration studies due to limited bioavailability data.
• AZD2461 is not a substitute for genetic knockdown or CRISPR-based pathway interrogation.
• It is not indicated for direct clinical translation without preclinical validation.

Workflow Integration & Parameters

To achieve optimal experimental outcomes, AZD2461 should be dissolved in DMSO or ethanol before dilution in culture medium. For in vitro studies, recommended concentrations range from 5 to 50 μM with incubation times of 48 to 72 hours. Cell lines such as MCF-7 and SKBR-3 have been validated as responsive models (Schwartz 2022). For in vivo research, doses between 5–10 mg/kg daily for up to 28 days are reported as effective and well-tolerated. Solutions should not be stored long-term and must be prepared fresh to maintain compound integrity. For further mechanistic and strategic deployment details, see AZD2461: Mechanistic Insights and Strategic Pathways, which this article extends by providing stepwise protocol recommendations.

For protocol troubleshooting and application-driven guidance, AZD2461: Next-Generation PARP Inhibitor outlines model selection and workflow refinement; our article clarifies these by detailing solubility and validated dosing parameters.

Conclusion & Outlook

AZD2461, available from APExBIO as SKU A4164, is a validated tool for dissecting PARP pathway biology and advancing breast cancer research. Its potent inhibition of PARP-1, low Pgp affinity, and favorable tolerability profile enable application in multidrug-resistant and relapse-prone cancer models. Future studies should focus on combinatorial regimens and further resistance profiling. For detailed mechanistic discussion and latest strategic deployment, researchers are encouraged to consult both this article and recent benchmarks in the translational literature.